...
首页> 外文期刊>Developmental Immunology: Journal of Immunology Research >N-TerminalPlasmodium vivaxMerozoite Surface Protein-1, a Potential Subunit for Malaria Vivax Vaccine
【24h】

N-TerminalPlasmodium vivaxMerozoite Surface Protein-1, a Potential Subunit for Malaria Vivax Vaccine

机译:N-末端间日疟原虫裂殖子表面蛋白-1,疟疾Vivax疫苗的潜在亚基

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The human malaria is widely distributed in the Middle East, Asia, the western Pacific, and Central and South America.Plasmodium vivaxstarted to have the attention of many researchers since it is causing diseases to millions of people and several reports of severe malaria cases have been noticed in the last few years. The lack ofin vitrocultures forP. vivaxrepresents a major delay in developing a functional malaria vaccine. One of the major candidates to antimalarial vaccine is the merozoite surface protein-1 (MSP1), which is expressed abundantly on the merozoite surface and capable of activating the host protective immunity. Studies have shown that MSP-1 possesses highly immunogenic fragments, capable of generating immune response and protection in natural infection in endemic regions. This paper shows humoral immune response to different proteins of PvMSP1 and the statement of N-terminal to be added to the list of potential candidates for malaria vivax vaccine.
机译:人类疟疾广泛分布于中东,亚洲,西太平洋以及中美洲和南美洲。间日疟原虫开始引起许多研究者的关注,因为它使数百万人罹患疾病,并且已有几起严重疟疾病例的报道。在最近几年中注意到。 P缺乏体外培养。 vivax代表了开发功能性疟疾疫苗的重大延迟。抗疟疾疫苗的主要候选药物之一是裂殖子表面蛋白-1(MSP1),该蛋白在裂殖子表面上大量表达,能够激活宿主的保护性免疫力。研究表明,MSP-1具有高度免疫原性的片段,能够在地方性地区的自然感染中产生免疫应答并提供保护。本文显示了对PvMSP1不同蛋白的体液免疫应答以及N末端的陈述将被添加到疟疾间质疫苗的潜在候选清单中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号